Kuriyama Y, Kawanishi Y, Iwase O, Nakano M, Toyama K
First Department of Internal Medicine, Tokyo Medical College.
Rinsho Ketsueki. 1994 May;35(5):487-94.
In non-Hodgkin's lymphoma (NHL), the precise analysis of non-neoplastic immunocompetent cells in lymph nodes may be important to understand the pathophysiology of anti-tumor immunity. We have investigated such immunocompetent cells of 14 patients with B-cell type NHL (B-NHL) by flow cytometry, and compared them with the data obtained from 10 patients with reactive lymphadenopathy. The results on B-NHLs were as follows; CD3+ (T lymphocyte) = 45.0 +/- 19.7%, CD4+/CD3+ = 62.7 +/- 14.2%, CD4+CD45RA-/CD4+ = 82.9 +/- 8.1% (Control 62.9 +/- 14.5%, p < 0.01), CD4+CD29++/CD4+ = 29.2 +/- 7.0% (Control 42.6 +/- 12.9%, p < 0.01), CD8+/CD3+ = 36.0 +/- 11.3%, CD8++S6F1++/CD3+ = 23.2 +/- 10.6% (Control 9.1 +/- 4.3%, p < 0.01), CD8++S6F1++/CD8++ = 75.3 +/- 16.7% (Control 41.5 +/- 19.6%, p < 0.01), CD3-CD56+ cells = 1.0 +/- 0.7% (Control 2.2 +/- 1.6%, p < 0.05). These findings suggest that CD4+ T lymphocytes in lymph nodes of B-NHL may change to memory cells (CD45RA- cells), but such memory cells could only weakly express CD29 molecules which are thought to play an important role in the manifestation of helper function. This phenotypic discordance of CD4+ T lymphocytes may produce incomplete anti-tumor immunity in B-NHL.
在非霍奇金淋巴瘤(NHL)中,精确分析淋巴结中的非肿瘤性免疫活性细胞对于理解抗肿瘤免疫的病理生理学可能很重要。我们通过流式细胞术研究了14例B细胞型NHL(B-NHL)患者的此类免疫活性细胞,并将其与10例反应性淋巴结病患者的数据进行了比较。B-NHL的结果如下:CD3 +(T淋巴细胞)= 45.0 +/- 19.7%,CD4 + / CD3 + = 62.7 +/- 14.2%,CD4 + CD45RA - / CD4 + = 82.9 +/- 8.1%(对照组62.9 +/- 14.5%,p < 0.01),CD4 + CD29 ++ / CD4 + = 29.2 +/- 7.0%(对照组42.6 +/- 12.9%,p < 0.01),CD8 + / CD3 + = 36.0 +/- 11.3%,CD8 ++ S6F1 ++ / CD3 + = 23.2 +/- 10.6%(对照组9.1 +/- 4.3%,p < 0.01),CD8 ++ S6F1 ++ / CD8 ++ = 75.3 +/- 16.7%(对照组41.5 +/- 19.6%,p < 0.01),CD3 - CD56 +细胞= 1.0 +/- 0.7%(对照组2.2 +/- 1.6%,p < 0.05)。这些发现表明,B-NHL淋巴结中的CD4 + T淋巴细胞可能转变为记忆细胞(CD45RA -细胞),但此类记忆细胞只能弱表达被认为在辅助功能表现中起重要作用的CD29分子。CD4 + T淋巴细胞的这种表型不一致可能在B-NHL中产生不完全的抗肿瘤免疫。